Skip to main content
Premium Trial:

Request an Annual Quote

Marina Ends Lease to Legacy R&D Facility for $1.2M in Stock

Premium

Marina Biotech said this week that it has terminated the lease to a Bothell, Wash., facility where the company conducted research and development related to its now-defunct intranasal drug operations.

Marina used the facility when it was Nastech Pharmaceutical, prior to its restructuring in 2008 as a pure-play RNAi and microRNA drug developer (GSN 5/08/2008). According to Marina President and CEO Michael French, the company hasn't occupied the building for three years.

According to a Marina filing with the US Securities and Exchange Commission, it signed an agreement with the building's owner to terminate the lease prior to its expiration date. In exchange, Marina will provide the landlord with 7.8 million shares of its common stock, which is currently trading around $0.15, a share for a total transaction value of about $1.2 million.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.